PathAI, a US-based global company involved in artificial intelligence powered technology for pathology, and Swiss-based Roche, a global pioneer in pharmaceuticals and diagnostics, announced on Friday that they have entered into a strategic collaboration to develop and distribute PathAI's AI-powered technology via Roche's uPath enterprise software.

This move is intended to allow broad access to digital pathology diagnostics to support clinical research and companion diagnostic (CDx) programs worldwide. The partnership between both firms is to provide a comprehensive menu of AI-powered digital pathology solutions in diagnostics.

The partnership is to initially include distribution of PathAI-developed research-use-only algorithms via NAVIFY Digital Pathology, the cloud version of Roche's uPath enterprise software, concentrating on immuno-oncology in multiple cancer types. It will also support biopharmaceutical partners with an end-to-end solution for CDx development, using Roche's diagnostic assays and pathology lab solutions with new and expanded innovative imaging tools from PathAI, in addition to the AI tools already offered by Roche.